Knešaurek Karin, Tuli Abbas, Kim Edward, Heiba Sherif, Kostakoglu Lale
Division of Nuclear Medicine, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1141, New York, NY, 10029, USA.
Division of Interventional Radiology, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, USA.
EJNMMI Phys. 2018 Aug 30;5(1):23. doi: 10.1186/s40658-018-0222-y.
The aim of our study was to compare Y dosimetry obtained from PET/MRI versus PET/CT post-therapy imaging among patients with primary or metastatic hepatic tumors. First, a water-filled Jaszczak phantom containing fillable sphere with Y-chloride was acquired on both the PET/CT and PET/MRI systems, in order to check the cross-calibration of the modalities. Following selective internal radiation therapy (SIRT) with Y microspheres, 32 patients were imaged on a PET/CT system, immediately followed by a PET/MRI study. Reconstructed images were transferred to a common platform and used to calculate Y dosimetry. A Passing-Bablok regression scatter diagram and the Bland and Altman method were used to analyze the difference between the dosimetry values.
The phantom study showed that both modalities were calibrated with less than 1% error. The mean liver doses for the 32 subjects calculated from PET/CT and PET/MRI were 51.6 ± 24.7 Gy and 46.5 ± 22.7 Gy, respectively, with a mean difference of 5.1 ± 5.0 Gy. The repeatability coefficient was 9.0 (18.5% of the mean). The Spearman rank correlation coefficient was very high, ρ = 0.97. Although the maximum dose to the liver can be significantly different (up to 40%), mean liver doses from each modalities were relatively close, with a difference of 18.5% or less.
The two main contributors to the difference in Y dosimetry calculations using PET/CT versus PET/MRI can be attributed to the differences in regions of interest (ROIs) and differences attributed to attenuation correction. Due to the superior soft-tissue contrast of MRI, liver contours are usually better seen than in CT images. However, PET/CT provides better quantification of PET images, due to better attenuation correction. In spite of these differences, our results demonstrate that the dosimetry values obtained from PET/MRI and PET/CT in post-therapy Y studies were similar.
我们研究的目的是比较原发性或转移性肝肿瘤患者治疗后成像中,PET/MRI与PET/CT所获得的钇剂量测定结果。首先,在PET/CT和PET/MRI系统上获取一个装有含氯化钇可填充球体的水填充Jaszczak体模,以检查各模态的交叉校准情况。在用钇微球进行选择性内照射治疗(SIRT)后,32例患者先在PET/CT系统上成像,随后立即进行PET/MRI检查。重建图像被传输到一个通用平台并用于计算钇剂量测定结果。采用Passing-Bablok回归散点图和Bland-Altman方法分析剂量测定值之间的差异。
体模研究表明,两种模态的校准误差均小于1%。从PET/CT和PET/MRI计算出的32名受试者的平均肝脏剂量分别为51.6±24.7 Gy和46.5±22.7 Gy,平均差值为5.1±5.0 Gy。重复性系数为9.0(占平均值的18.5%)。Spearman等级相关系数非常高,ρ = 0.97。虽然肝脏的最大剂量可能有显著差异(高达40%),但各模态的平均肝脏剂量相对接近,差异在18.5%或更小。
使用PET/CT与PET/MRI进行钇剂量测定计算结果存在差异的两个主要原因可归因于感兴趣区域(ROI)的差异以及衰减校正的差异。由于MRI具有出色的软组织对比度,肝脏轮廓通常比CT图像中看得更清楚。然而,由于衰减校正更好,PET/CT能对PET图像进行更好的定量分析。尽管存在这些差异,但我们的结果表明,在治疗后钇研究中,PET/MRI和PET/CT获得的剂量测定值相似。